A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Escalating Trial to Evaluate the Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Verdinexor (Primary)
- Indications Viral infections
- Focus Adverse reactions
- Sponsors Karyopharm Therapeutics
- 21 Oct 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.
- 24 Sep 2015 Status changed from completed to recruiting, as reported by ClinicalTrials.gov.
- 15 Sep 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.